20.52

0.15% -0.025

Enliven Therapeutics Inc (ELVN)

Overview News Price History Option Chain Financials Discussions Forecast

Enliven Therapeutics Inc stock is traded at $20.52, with a volume of 208.83K. It is down -0.15% in the last 24 hours and up +6.88% over the past month. Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Previous Close:

$20.55

Open:

$20.75

24h Volume:

208.83K

Relative Volume:

0.45

Market Cap:

$1.21B

Revenue:

Net Income/Loss:

$-85.21M

P/E Ratio:

-10.86

EPS:

-1.89

Net Cash Flow:

$-68.53M

1W Performance:

-4.16%

1M Performance:

+6.88%

6M Performance:

+12.13%

1Y Performance:

-29.19%

1-Day Range:

$20.32

$20.81

1-Week Range:

$20.10

$22.36

52-Week Range:

$13.30

$29.79

Enliven Therapeutics Inc Stock (ELVN) Company Profile

Name

Enliven Therapeutics Inc

Sector

Healthcare (1145)

Industry

Biotechnology (642)

Phone

720-647-8519

Address

6200 LOOKOUT ROAD, BOULDER

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

ELVN's Discussions on Twitter

Compare ELVN with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ELVN Enliven Therapeutics Inc	20.51	1.22B	0	-85.21M	-68.53M	-1.89
VRTX Vertex Pharmaceuticals Inc	422.77	109.29B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	461.25	60.82B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	579.50	61.02B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	810.58	51.39B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	309.94	34.68B	4.56B	-176.77M	225.30M	-1.7177

Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-16-25	Initiated	Goldman	Buy
Dec-13-24	Initiated	BTIG Research	Buy
Sep-09-24	Initiated	H.C. Wainwright	Buy
Jun-11-24	Initiated	Robert W. Baird	Outperform
Apr-09-24	Initiated	Mizuho	Buy
Mar-29-23	Initiated	Jefferies	Buy

View All

Enliven Therapeutics Inc Stock (ELVN) Latest News

09:45 AM

Enliven Therapeutics Inc. recovery potential after sell offQuarterly Trade Summary & Daily Price Action Insights - newser.com

09:45 AM

06:08 AM

Is Enliven Therapeutics Inc. stock positioned well for digital economyWeekly Trade Recap & Stepwise Entry and Exit Trade Signals - newser.com

06:08 AM

05:54 AM

Applying sector rotation models to Enliven Therapeutics Inc.July 2025 Intraday Action & Free Fast Gain Swing Trade Alerts - newser.com

05:54 AM

05:26 AM

Is Enliven Therapeutics Inc. stock a safe haven asset2025 Earnings Surprises & Community Consensus Trade Alerts - newser.com

05:26 AM

01:37 AM

Why Enliven Therapeutics Inc. stock appeals to dividend seekersWeekly Profit Recap & Verified Trade Idea Suggestions - newser.com

01:37 AM

Oct 23, 2025

Assessing Enliven Therapeutics (ELVN) Valuation as Shares Show Signs of Short-Term Momentum - Yahoo Finance

Oct 23, 2025

Real time breakdown of Enliven Therapeutics Inc. stock performanceEarnings Trend Report & Weekly High Return Forecasts - newser.com

Oct 23, 2025

Is Enliven Therapeutics Inc. stock cheap compared to fundamentalsFed Meeting & Target Return Focused Stock Picks - newser.com

Oct 23, 2025

Enliven Therapeutics Insider Sold Shares Worth $276,025, According to a Recent SEC Filing - MarketScreener

Oct 23, 2025

Published on: 2025-10-23 01:40:18 - newser.com

Oct 23, 2025

Oct 22, 2025

Lyssikatos, chief scientific officer, sells Enliven Therapeutics shares By Investing.com - Investing.com Canada

Oct 22, 2025

Brokerages Set Enliven Therapeutics, Inc. (NASDAQ:ELVN) Price Target at $41.20 - Defense World

Oct 22, 2025

Oct 21, 2025

Enliven Therapeutics CEO Kintz sells $266k in shares By Investing.com - Investing.com UK

Oct 21, 2025

ELVN insider sale: 12,500 shares sold; 902,892 shares remain held - Stock Titan

Oct 21, 2025

Is now a turning point for Enliven Therapeutics Inc.Global Markets & Risk Controlled Daily Plans - newser.com

Oct 21, 2025

Strategies to average down on Enliven Therapeutics Inc.Quarterly Profit Review & AI Powered Market Trend Analysis - newser.com

Oct 21, 2025

How to read the order book for Enliven Therapeutics Inc.2025 Institutional Moves & Verified Entry Point Signals - newser.com

Oct 21, 2025

Oct 20, 2025

Automated trading signals detected on Enliven Therapeutics Inc.Market Sentiment Report & Free Low Drawdown Momentum Trade Ideas - newser.com

Oct 20, 2025

Oct 18, 2025

Trading Recap: Why retail investors favor Enliven Therapeutics Inc. stockEarnings Overview Summary & Verified Momentum Stock Watchlist - nchmf.gov.vn

Oct 18, 2025

Will Enliven Therapeutics Inc. stock rally after Fed decisions2025 Key Lessons & Real-Time Chart Pattern Alerts - nchmf.gov.vn

Oct 18, 2025

Will Enliven Therapeutics Inc. stock split again soon2025 Market WrapUp & Reliable Breakout Forecasts - nchmf.gov.vn

Oct 18, 2025

Will Enliven Therapeutics Inc. stock outperform tech sector in 2025July 2025 Institutional & Pattern Based Trade Signal System - nchmf.gov.vn

Oct 18, 2025

Heatmap analysis for Enliven Therapeutics Inc. and competitorsWatch List & Target Return Focused Picks - newser.com

Oct 18, 2025

Oct 17, 2025

Why retail investors favor Enliven Therapeutics Inc. stockWeekly Loss Report & Daily Profit Focused Screening - nchmf.gov.vn

Oct 17, 2025

Will Enliven Therapeutics Inc. stock continue dividend increases2025 Performance Recap & Daily Entry Point Trade Alerts - nchmf.gov.vn

Oct 17, 2025

(ELVN) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com

Oct 17, 2025